

# Dietary interventions for irritable bowel syndrome

<b>Submission date</b> 27/06/2012	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/08/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 16/11/2020	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Irritable bowel syndrome (IBS) is a digestive disorder that affects up to 15% of the population. Symptoms include stomach pain, bloating and altered bowel habit. It can be very debilitating and has a great impact on quality of life. A diet with an altered amount of carbohydrates (e.g. the types of fruits and vegetables) might be effective for symptoms such as bloating, stomach pain and flatulence for many people with IBS. Recent research has shown that the diet described above can impact on the amount of bifidobacteria in the bowel. Probiotics are friendly bacteria added to foods that can increase the amount of bifidobacteria in the bowel. This study will investigate the effect of this diet with a probiotic food supplement on:

1. Bacteria in the bowel and the products of bacterial fermentation
2. Gut symptoms (e.g. wind, bloating)
3. Stool frequency and consistency
4. Dietary intake
5. Quality of life

The effect of dietary change on symptoms and the bacteria in the bowel in the longer term will also be studied.

### Who can participate?

Patients of Guy's and St Thomas' NHS Foundation Trust or St George's Healthcare Trust aged 18-65 with IBS

### What does the study involve?

The study incorporates three study centre visits, one before the 4-week study period, one after the 4-week study period and one visit at 12 months. There may also need to be one initial visit prior to the baseline visit in order to obtain consent if the patient is not identified in clinic, but screened from the referral letter.

### What are the possible benefits and risks of participating?

There are no anticipated risks to participants; however, changes to dietary intake will be required for a 4-week period. Two stool samples will be collected and symptom, food and quality of life questionnaires will need to be completed. Routine dietary advice will be provided at the end of the study to all patients as per routine clinical care.

Where is the study run from?

The study will be run from King's College London and St George's Healthcare Trust

When is the study starting and how long is it expected to run for?

Recruitment will continue until September 2014

Who is funding the study?

National Institute for Health Research (NIHR) (UK)

Who is the main contact?

Heidi Staudacher, Research Dietitian

heidi.staudacher@kcl.ac.uk

## Contact information

### Type(s)

Scientific

### Contact name

Ms Heidi Staudacher

### Contact details

King's College London  
Franklin Wilkins Building  
150 Stamford Street  
London  
United Kingdom  
SE1 9NH

## Additional identifiers

### Protocol serial number

N/A

## Study information

### Scientific Title

The impact of dietary interventions for irritable bowel syndrome on luminal microbiota, symptoms, nutrient intake and quality of life: a randomised controlled trial

### Study objectives

Current study hypothesis as of 24/01/2013:

There is no difference in luminal bifidobacteria concentration between participants after four weeks of a sham diet versus four weeks of a treatment diet with added probiotic.

Previous study hypothesis until 24/01/2013:

There is no difference in luminal bifidobacteria concentration between participants after four weeks of a sham diet versus four weeks of a fermentable carbohydrate restriction with added probiotic.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

NRES Committee London-Fulham, 08/10/2012, ethics no. 12/LO/1402

**Study design**

2 x 2 factorial design randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Irritable bowel syndrome

**Interventions**

Current interventions as of 24/01/2013:

4-week treatment diet + placebo

4-week treatment diet + added probiotic

4-week week sham diet + placebo

4-week sham diet + added probiotic

Previous interventions until 24/01/2013:

4-week fermentable carbohydrate restriction + placebo

4-week fermentable carbohydrate restriction + added probiotic

4-week week sham diet + placebo

4-week sham diet + added probiotic

**Intervention Type**

Mixed

**Primary outcome(s)**

1. Luminal bifidobacteria concentration between groups at 4 weeks

Added 05/08/2014:

2. Proportion of participants with adequate relief of IBS symptoms at 4 weeks

**Key secondary outcome(s))**

1. Difference in total and individual luminal gastrointestinal microbiota at 4 weeks

2. Difference in faecal short chain fatty acids and pH between groups at 4 weeks

3. Difference in IBS symptoms between groups at 4 weeks

4. Difference in stool consistency between groups at 4 weeks

5. Difference in nutrient intake between groups at 4 weeks

6. Difference in quality of life (QOL) scores between groups at 4 weeks

**Completion date**

30/09/2014

# Eligibility

## Key inclusion criteria

1. Men and women aged 18-65 years with IBS-D, IBS-M or unsubtyped IBS based on Rome III criteria who do not have a major medical condition (diabetes, psychiatric or current eating disorders)
2. Gastrointestinal disease (e.g. inflammatory bowel disease, coeliac disease)
3. History of previous GI surgery, except cholecystectomy and haemorrhoidectomy

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Lower age limit

18 years

## Upper age limit

65 years

## Sex

All

## Total final enrolment

95

## Key exclusion criteria

1. Females who report to be pregnant or lactating
2. Consumption of antibiotics, pre or probiotics (in food products or as supplements) in the last 4 weeks prior to, or during the study
3. Use of unpermitted medications (e.g. biological therapies)
4. Patients who have received bowel preparation for investigative procedures in the 4 weeks prior to the study
5. Patients who have had changes to IBS medications or dose in the 4 weeks prior to the study
6. Abdominal pain or discomfort for less than 2 days in the screening week, the frequency threshold recommended for clinical trials. Exclusion of those with minimal symptoms is recommended, and only those that experience pain on at least two days will be included.
7. Individuals with additional specific dietary needs

## Date of first enrolment

01/09/2012

## Date of final enrolment

30/09/2014

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

King's College London

London

United Kingdom

SE1 9NH

**Sponsor information****Organisation**

King's College London (UK)

**ROR**

<https://ror.org/0220mzb33>

**Funder(s)****Funder type**

Government

**Funder Name**

National Institute for Health Research

**Alternative Name(s)**

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2017		Yes	No
<a href="#">Results article</a>	results	01/03/2018		Yes	No
<a href="#">Results article</a>	results	23/10/2020	16/11/2020	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes